Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.
about
Statins for primary prevention of venous thromboembolismStatins for the primary prevention of cardiovascular diseaseStatins for primary prevention of venous thromboembolismRosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspectiveStatins for primary cardiovascular prevention in the elderlyOrigin and therapy for hypertriglyceridaemia in type 2 diabetesReverse Epidemiology of Traditional Cardiovascular Risk Factors in the Geriatric PopulationPersonalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling studyCancer risk in older people receiving statin therapy: a meta-analysis of randomized controlled trialsStatins for Primary Prevention in Older Adults: Uncertainty and the Need for More EvidenceAtherosclerotic Cardiovascular Disease Risk and Evidence-based Management of Cholesterol.Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.Lipid-lowering treatment to the end? A review of observational studies and RCTs on cholesterol and mortality in 80+-year olds.Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥ 5% or Framingham risk >20%: post hoc analyses of the JUPITER trial requested by European health authoritiesStatinopause.Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease.Workplace based mindfulness practice and inflammation: a randomized trial.Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly.The JUPITER lipid lowering trial and vitamin D: Is there a connection?External validation of an index to predict up to 9-year mortality of community-dwelling adults aged 65 and older.JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses.The Effect of Elevated Triglycerides on the Onset and Progression of Coronary Artery Disease: A Retrospective Chart Review.Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional studyRelation between serum total cholesterol level and cardiovascular disease stratified by sex and age group: a pooled analysis of 65 594 individuals from 10 cohort studies in Japan.Cholesterol and cardiovascular disease in the elderly. Facts and gaps.Stereoselective binding of chiral drugs to plasma proteinsMoving beyond JUPITER: will inhibiting inflammation reduce vascular event rates?PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016.Targets for body fat, blood pressure, lipids, and glucose-lowering interventions in healthy older people.Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.Initiation of statin therapy: are there age limits?Cardiovascular disease, statins and vitamin D.The evolution or revolution of statin therapy in primary prevention: where do we go from here?Searching the place of pitavastatin in the current treatment of patients with dyslipidemia.An update on the benefits and risks of rosuvastatin therapy.Primary prevention of cardiovascular disease with statins in the elderly.Aggressive lipid management in very elderly adults: less is more.Statins in the elderly: a patient-focused approach.What the guidelines do not say: statin non-benefit groups.
P2860
Q24187238-115ACD4B-444A-45EB-8AF3-826680E6BFCCQ24201513-6EFB00FE-81A7-44F8-BA7E-2FBFB76F8DCFQ24204040-339AD985-005F-497C-A7E3-53172D7AFA71Q24594814-1D2FED75-0283-45F6-94B8-73141D48674BQ26783401-2E3E902D-CE6A-4C93-ABCF-A16A372EF78BQ26824004-2D5073CF-B236-4309-BC49-911ACB99EB56Q28081914-CB9FA252-61BC-4E02-A150-62ABF20E9D30Q28484624-14E13164-3EB2-4543-BE05-C519E6AF22FAQ28821882-48AFDF76-5688-414C-9ACF-161AE15E7FF7Q33675377-E460DD03-2983-446E-942C-E1A3F3598F48Q33724722-D787B027-BEDB-4F72-A7FF-623240992D9DQ33972551-333F8D67-601D-4426-985E-64C015544016Q34207468-C6D16BE6-8311-4A49-A304-7A77B0C13AC9Q34293369-903549F1-1C5D-4243-8633-1E0984627AB6Q34453538-69D80DC5-246C-417E-A633-C2EC329587F1Q34566869-A9798D8B-479F-4947-9D4B-AB015BEBE577Q34636887-0096A9B2-759E-4FBB-8039-9B9D032226E3Q34644166-B1353F08-7FD9-4916-9367-B2EBE24992C1Q34733233-A970B0BE-BCF6-4E68-86F3-D5EF1F722554Q34847190-1BFC75EF-F6A8-4574-A553-84520653A5EEQ35171219-99C64B06-31FD-4AC5-BF4A-60BACD40F348Q35172886-4934C33F-5EE1-41B7-9F13-C326AEDBE883Q35855308-945C3850-D988-47B0-A422-A3B5926EB480Q36091989-E1FC73A2-3FF5-4B7B-9C24-6325795F7FC2Q36522704-1109F4A2-9094-43DD-809C-9757858BEB83Q36863052-A69CEE6E-E270-42BE-8FCA-5F02B977D424Q37069257-E1995BAF-C7E9-4E72-8CBC-52082DF6759BQ37279687-603B572B-D4BB-44E0-8DD1-4991A758C5E8Q37549374-675C7990-4B81-42FC-A50B-C96295892851Q37577151-25155D9C-DF2D-4EC3-B40C-258A9403CDC0Q37810896-5574D049-5F13-47BE-84CE-16EFE942ADF4Q37956537-6FD6D073-A6F6-4515-92D9-6A58FE2A6586Q37991512-C75C4EDF-8B16-430F-9AD8-3C329D61BE22Q38072612-3D44A0D9-8351-4FF4-8672-396174765319Q38161516-27EA0FA1-BA56-4F18-973B-4B3252D34856Q38200826-CF1A893B-E5F0-46B3-A1EB-6F57FCD02B8DQ38208222-2FB2C46A-1F9C-4A6E-ADAD-DB98CFDFA96EQ38209732-64BC2FFC-3ACA-4687-B777-123E7F140EE2Q38261869-84EBBE43-5AD0-4C7D-8365-9A9A5B184B60Q38268914-5A91A84F-8299-441A-9036-2C06B6E7FB51
P2860
Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Rosuvastatin for primary preve ...... nalysis of a randomized trial.
@ast
Rosuvastatin for primary preve ...... nalysis of a randomized trial.
@en
Rosuvastatin for primary preve ...... nalysis of a randomized trial.
@nl
type
label
Rosuvastatin for primary preve ...... nalysis of a randomized trial.
@ast
Rosuvastatin for primary preve ...... nalysis of a randomized trial.
@en
Rosuvastatin for primary preve ...... nalysis of a randomized trial.
@nl
prefLabel
Rosuvastatin for primary preve ...... nalysis of a randomized trial.
@ast
Rosuvastatin for primary preve ...... nalysis of a randomized trial.
@en
Rosuvastatin for primary preve ...... nalysis of a randomized trial.
@nl
P2093
P2860
P1476
Rosuvastatin for primary preve ...... nalysis of a randomized trial.
@en
P2093
James Shepherd
Paul M Ridker
Robert J Glynn
P2860
P304
488-96, W174
P356
10.7326/0003-4819-152-8-201004200-00005
P407
P577
2010-04-01T00:00:00Z